Celularity Inc.

NASDAQ:CELU

Biotechnology

Healthcare
$1.83 +138.53%

+$1.22 today

Market cap
$52.97M
Beta
0.54
P/E (TTM)
-0.6
EPS (TTM)
-$3.58
52W Low $0.56High $4.00

Volume 0.00M

Average 0.13M

CELU Total Assets

Everything the company owns or controls; equal to total liabilities plus equity.

Celularity Inc.NASDAQ: CELU

Total Assets · Q4 FY2025 · quarter ended Dec 2025

Total assets falls 19.1% from a year ago

Total assets stood at $107.33M at the end of Q4 FY2025, down 19.1% from a year earlier and down 6.0% from the prior quarter. Over 3 fiscal years it compounded at -35.6% a year.

Context

  • Total assets increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total assets keeps falling in the next quarterly balance sheet after a -19.1% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterDec 2025
$107.33M-6.0% QoQ
Last fiscal yearDec 2025
$107.33M-19.1% YoY
Year agoDec 2024
$132.68M-19.1% since
Total Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-19.1%——
1 year-19.1%——
3-year CAGR-35.6%——
5-year CAGR——
10-year CAGR——

Total Assets history

USD · from the balance sheet

Latest · FY2025
107.33M USD
Year-over-year change
-19.1%
4-year CAGR
-28.6%

Total Assets vs competitors

How CELU compares with its peers on the latest reported figures

  • CELU's Dec 2025 total assets of $107.33M is the highest of the 4 companies compared; the peer median is $19.16M.
  • Its year-over-year change of -19.1% is the 2nd highest of 4, against a peer median of -36.3%.
  • Over three fiscal years its annual growth of -35.6% compares with a peer median of -16.4%.
CELU Competitors Peer median
Total Assets for CELU and competitors
Company Period Latest balance YoY 3-year CAGR
CELUCelularity Inc.Dec 2025$107.33M -19.1%-35.6%
ATNMActinium Pharmaceuticals, Inc.Jun 2026$40.16M -36.3%-23.2%
PYPDPolyPid Ltd.Mar 2026$19.16M +13.7%-4.9%
ANVSAnnovis Bio, Inc.Mar 2026$16.24M -39.2%-16.4%
Peer median (excluding CELU) $19.16M-36.3%-16.4%

Competitors are the stored peer set for CELU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents37.24M13.97M227K738K6.18M
Short-term Investments00000
Net Receivables5.23M6.97M12.12M13.56M4.65M
Inventory9.55M5.31M5.75M5.41M571K
Other Current Assets2K1.05M329K857K222K
Total Current Assets59.1M33.5M19.79M20.56M12.32M
Property, Plant & Equipment (Net)90.63M88.72M78.82M72.43M66.52M
Goodwill123.3M119.69M7.35M7.35M7.35M
Intangible Assets123.19M120.99M11M9.25M7.76M
Long-term Investments14.84M14.84M9.94M10.24M0
Tax Assets09K(9.94M)00
Other Non-current Assets3.08M23.32M26.93M12.86M13.39M
Total Non-current Assets355.03M367.56M124.1M112.12M95.01M
Total Assets414.13M401.07M143.89M132.68M107.33M
Account Payables9.32M5.81M14.14M23.3M26.42M
Short-term Debt3.05M37.6M39.24M6.36M14M
Tax Payables00000
Deferred Revenue2.2M2.27M2.83M3.53M5.26M
Other Current Liabilities7.84M13.83M8.07M1.61M6.93M
Total Current Liabilities26.23M62.09M67.3M53.68M80.76M
Long-term Debt00035.93M0
Deferred Tax Liabilities10K9K9K9K12K
Deferred Revenue (Non-current)1.87M2.22M3.19M2.72M2.8M
Other Non-current Liabilities258.52M109.86M6.26M4.96M34.92M
Total Non-current Liabilities288.48M140.08M35.63M70.17M64.63M
Total Liabilities314.71M202.17M102.93M123.85M145.39M
Common Stock12K15K19K2K3K
Retained Earnings(663.68M)(645.5M)(841.79M)(899.68M)(991.48M)
Accumulated OCI09K0(5K)0
Other Stockholders Equity00000
Minority Interest00000
Total Equity99.42M198.9M40.96M8.84M(38.06M)
Total Debt31.14M65.59M65.42M68.84M40.9M
Net Debt(6.1M)51.62M65.19M68.1M34.73M

Celularity Inc.

NASDAQ:CELU

Intrinsic Alpha fair value

Locked

Current Price

$1.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.